Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010596 | 0.98 | HTR1B (0.41) | HTR1BSIGMAR1HTR1DALDH1A1CNR1 | |
| SCHEMBL5010705 | 0.94 | HTR1B (0.46) | HTR1BSIGMAR1HTR1DALDH1A1KMT2A | |
| SCHEMBL5012205 | 0.89 | SIGMAR1 (0.42) | HTR1BSIGMAR1HTR1DALDH1A1KMT2A | |
| SCHEMBL2338566 | 0.82 | SIGMAR1 (0.47) | SIGMAR1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL28680127 | 0.81 | HTR1B (0.44) | HTR1BSIGMAR1HTR1DALDH1A1KDM4E | |
| SCHEMBL28159089 | 0.81 | HTR1B (0.44) | HTR1BSIGMAR1HTR1DALDH1A1KDM4E | |
| SCHEMBL27875483 | 0.81 | HTR1B (0.44) | HTR1BSIGMAR1HTR1DALDH1A1KDM4E | |
| SCHEMBL28753645 | 0.80 | HTR1B (0.47) | HTR1BSIGMAR1HTR1DALDH1A1KDM4E | |
| SCHEMBL10490426 | 0.80 | HTR1B (0.47) | HTR1BSIGMAR1HTR1DALDH1A1KDM4E | |
| SCHEMBL10490532 | 0.80 | SIGMAR1 (0.46) | HTR1BSIGMAR1HTR1DALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | HTR1B 4003/4885SIGMAR1 1156/4885HTR1D 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.